1. Home
  2. LDWY vs CERO Comparison

LDWY vs CERO Comparison

Compare LDWY & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LDWY
  • CERO
  • Stock Information
  • Founded
  • LDWY 1990
  • CERO 2017
  • Country
  • LDWY United States
  • CERO United States
  • Employees
  • LDWY N/A
  • CERO N/A
  • Industry
  • LDWY Advertising
  • CERO
  • Sector
  • LDWY Consumer Discretionary
  • CERO
  • Exchange
  • LDWY Nasdaq
  • CERO Nasdaq
  • Market Cap
  • LDWY 8.2M
  • CERO 8.4M
  • IPO Year
  • LDWY 1991
  • CERO N/A
  • Fundamental
  • Price
  • LDWY $4.25
  • CERO $1.92
  • Analyst Decision
  • LDWY
  • CERO
  • Analyst Count
  • LDWY 0
  • CERO 0
  • Target Price
  • LDWY N/A
  • CERO N/A
  • AVG Volume (30 Days)
  • LDWY 4.4K
  • CERO 787.1K
  • Earning Date
  • LDWY 03-31-2025
  • CERO 02-20-2025
  • Dividend Yield
  • LDWY N/A
  • CERO N/A
  • EPS Growth
  • LDWY N/A
  • CERO N/A
  • EPS
  • LDWY N/A
  • CERO N/A
  • Revenue
  • LDWY $31,581,000.00
  • CERO N/A
  • Revenue This Year
  • LDWY N/A
  • CERO N/A
  • Revenue Next Year
  • LDWY N/A
  • CERO N/A
  • P/E Ratio
  • LDWY N/A
  • CERO N/A
  • Revenue Growth
  • LDWY N/A
  • CERO N/A
  • 52 Week Low
  • LDWY $3.02
  • CERO $1.76
  • 52 Week High
  • LDWY $6.88
  • CERO $1,238.00
  • Technical
  • Relative Strength Index (RSI)
  • LDWY 47.81
  • CERO 33.62
  • Support Level
  • LDWY $4.13
  • CERO $1.77
  • Resistance Level
  • LDWY $4.55
  • CERO $2.22
  • Average True Range (ATR)
  • LDWY 0.22
  • CERO 0.36
  • MACD
  • LDWY -0.02
  • CERO 0.29
  • Stochastic Oscillator
  • LDWY 39.98
  • CERO 11.27

About LDWY Lendway Inc. (DE)

Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Share on Social Networks: